Pharmacological agents that inhibit these pathways, such as erlotinib (EGFR inhibitor), NVP-BEZ235 (PI3K/mTOR dual inhibitor), or cannabidiol (Akt/mTOR modulator), have shown synergistic effects with gemcitabine in preclinical models of CCA. Here, EGFR is linked to cholangiocarcinoma.